Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1969 4
1970 4
1971 4
1972 2
1973 3
1974 2
1975 2
1978 1
1979 2
1980 1
1981 1
1982 6
1983 6
1986 1
1987 2
1988 7
1989 2
1990 7
1991 1
1992 11
1993 2
1994 4
1995 7
1996 24
1997 34
1998 53
1999 50
2000 29
2001 46
2002 42
2003 46
2004 59
2005 65
2006 78
2007 49
2008 29
2009 31
2010 33
2011 40
2012 36
2013 33
2014 39
2015 38
2016 33
2017 30
2018 29
2019 37
2020 35
2021 35
2022 40
2023 17
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 17307771

1,118 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A. Ribera E, et al. J Antimicrob Chemother. 2007 Apr;59(4):690-7. doi: 10.1093/jac/dkl552. Epub 2007 Feb 16. J Antimicrob Chemother. 2007. PMID: 17307771
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A. Ribera E, et al. Antimicrob Agents Chemother. 2004 Nov;48(11):4256-62. doi: 10.1128/AAC.48.11.4256-4262.2004. Antimicrob Agents Chemother. 2004. PMID: 15504850 Free PMC article. Clinical Trial.
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T. Bickel M, et al. J Antimicrob Chemother. 2009 Dec;64(6):1260-4. doi: 10.1093/jac/dkp348. Epub 2009 Sep 22. J Antimicrob Chemother. 2009. PMID: 19776037
Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
Moltó J, Llibre JM, Ribera E, Mínguez C, del Río JS, Pedrol E, Vallecillo G, Cedeño S, Valle M, Miranda C, Negredo E, Clotet B; SQV-HEP Study Group. Moltó J, et al. J Antimicrob Chemother. 2009 May;63(5):992-7. doi: 10.1093/jac/dkp070. Epub 2009 Mar 11. J Antimicrob Chemother. 2009. PMID: 19279052
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW, Becker S, King MS, da Silva B, Klein C, Tokimoto D, Foit C, Calhoun D, Bernstein B, Hanna GJ. Cameron DW, et al. J Antimicrob Chemother. 2007 May;59(5):957-63. doi: 10.1093/jac/dkm029. Epub 2007 Mar 9. J Antimicrob Chemother. 2007. PMID: 17350990 Clinical Trial.
Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, Cooper D, Lange J, Phanuphak P, Ruxrungtham K, Burger D. Autar RS, et al. J Antimicrob Chemother. 2004 Oct;54(4):785-90. doi: 10.1093/jac/dkh415. Epub 2004 Aug 25. J Antimicrob Chemother. 2004. PMID: 15329366 Clinical Trial.
1,118 results